Drugs / Zimberelizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05540483 | Aug 2022 → Aug 2024 | bile duct carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zimberelizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05540483 ↗ |
| Known as | GLS-010 | “Disitamab Vedotin（RC-48 ）Combined With Zimberelizumab（GLS-010） in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer” NCT05540483 ↗ |
| Route | Intravenous | “Zimberelizumab, 240mg, intravenously D1” NCT05540483 ↗ |